anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the technical fields of drugs for treating anaphylactic purpura, aims to solve the problems of bad curative effect, strong side effect, long treatment course, and high cost existing in the conventional drugs for treating anaphylactic purpura, and provides a traditional Chinese medicine preparation for curing anaphylactic purpura caused by blood-heat congestion. The traditional Chinese medicine preparation is prepared from raw rehmannia root charcoal, herba cephalanoploris charcoal, sophora flower charcoal, ginger charcoal, mixed-fried radix astragali, cassia twig, white peony root, red sage root, radix scrophulariae, lumbricus, cyperus rotundus, and jujube according to a certain ratio. The traditional Chinese medicine preparation is mainly used for treating purpura in the acute phase when the blood-heat is congested, thus the blood is forced to circulate randomly in the human body, and flows out from the vessels. Raw rehmannia root charcoal, herba cephalanoploris charcoal, sophora flower charcoal, and ginger charcoal have the functions of clearing heat, cooling blood, dispelling stasis, and generating new tissues; ginger charcoal and cassia twig have the functions of harmonizing yang and relieving dyspepsia; mixed-fried radix astragali has the functions of tonifying qi, securing the exterior, and boosting blood; white peony root and radix scrophulariae have the functions of nourishing yin and cooling blood, red sage root has the functions of cooling blood and promoting blood circulation, lumbricus has the functions of freeing the collateral vessels and activating blood, cyperus rotundus has the functions of regulating qi and promoting blood circulation, and jujube has the functions of tonifying spleen, tonifying qi, and nourishing blood. The medicinal materials mentioned above cooperate with each other to have a synergic effect so as to have functions of freeing the collateral vessels and eliminating speckles. The effective rate of the traditional Chinese medicine on treating anaphylactic purpura caused by blood-heat congestion reaches 92% or more. The traditional Chinese medicine preparation has the advantages of user-friendliness and satisfactory curative effect.
Neuroinflammation and mitochondrial dysfunction are closely intertwined with the pathophysiology of neurological disorders. Recent studies have elucidated profound alterations in mitochondrial dynamics across a spectrum of neurological disorders. Dynamin-related protein 1 (DRP1) emerges as a pivotal regulator of mitochondrial fission, with its dysregulation disrupting mitochondrial homeostasis and fueling neuroinflammation, thereby exacerbating disease severity. In addition to its role in mitochondrial dynamics, DRP1 plays a crucial role in modulating inflammation-related pathways. This review synthesizes important functions of DRP1 in the central nervous system (CNS) and the impact of epigenetic modification on the progression of neurodegenerative diseases. The intricate interplay between neuroinflammation and DRP1 in microglia and astrocytes, central contributors to neuroinflammation, is expounded upon. Furthermore, the use of DRP1 inhibitors to influence the activation of microglia and astrocytes, as well as their involvement in processes such as mitophagy, mitochondrial oxidative stress, and calcium ion transport in CNS-mediated neuroinflammation, is scrutinized. The modulation of microglia to astrocyte crosstalk by DRP1 and its role in inflammatory neurodegeneration is also highlighted. Overall, targeting DRP1 presents a promising avenue for ameliorating neuroinflammation and enhancing the therapeutic management of neurological disorders.
The proposed research will be undertaken as a double-blind randomized cross-over study with participants being subjected to 2 consecutive treatments of 4 weeks each, in random order, during which they will consume 45g of buttermilk and a macro- and micronutrient matching placebo. The treatments will be different in their content of MFGM (present in buttermilk, absent in placebo). Buttermilk and placebo will be fully characterized and formulated in ready-to-use pouches, each pouch containing 22.5 g of artificially flavored products that will have to be mixed in a fixed amount of water for consumption. Participants will have to consume two pouches every day. Based on a 2500 kcal/day regimen, we have calculated that these placebo and buttermilk formulation will contribute to approximately 200 kcal (from 5% and 10%) of the daily energy intake of participants, who will be asked to maintain other aspects of their nutritional habits constant throughout the study.

Fluctuations in female hormones have been shown to influence metabolic variables. For that reason, outcomes at the end of each dietary phase will be measured during the follicular phase of menstrual cycle (day 3 to day 9) in pre-menopausal women. This is another argument for using a 4-wk intervention, which essentially corresponds to the mean duration of the menstrual cycle of most women. Pre-menopausal women will start the first diet during the first week of their menstrual cycle.
The invention discloses a D-type polypeptide of a targeted anti-double-stranded DNA antibody and application thereof in preparing a therapeutic drug for systemic lupus erythematosus. The invention verifies the targeting binding activity, enzymolysis resistance stability and improving effect on lupus nephritis of the D-type polypeptide in vitro and in vivo. Experimental results prove that the polypeptide D-ALW can target different subtypes of the anti-double-stranded DNA antibody and widely inhibit the pathogenic effect of the anti-double-stranded DNA antibody. The polypeptide can be combined with different subtype anti-double-stranded DNA antibodies with high affinity at an in vitro level, and can effectively inhibit the combination of the different subtype anti-double-stranded DNA antibodies with autoantigens, renal cells and glomeruli. The polypeptide D-ALW has better enzyme digestion stability. In vivo studies prove that the polypeptide D-ALW can significantly improve the damage of the lupus nephritis of mice. The D-type polypeptide of the invention can provide a new choice for preparing targeted therapeutic drugs for clinical systemic lupus erythematosus, especially refractory lupus nephritis.
PURPOSE OF REVIEW: Lacrimal neuralgia is a rare periorbital neuralgia. To date, only nine cases have been reported in the literature. Herein, we report a case and a comprehensive overview of the entity with a focus on the differential diagnosis of lacrimal neuralgia. Additionally, we propose putative diagnostic criteria for this rare neuralgia based on cases that have been reported.
RECENT FINDINGS: Among the ten cases of lacrimal neuralgia reported (including the one in this review), seven out of ten were idiopathic, and the other three were considered secondary. Most patients reported stabbing and shooting pain that was either paroxysmal or continuous. The most effective therapy was nerve block for seven patients and pregabalin for three patients. The most important clues to differentiate lacrimal neuralgia from other causes of periorbital pain include pain topography and pain with features suggestive of neuralgia. The core feature of lacrimal neuralgia is neuralgic pain located in the area supplied by the lacrimal nerve, and the etiology could be primary or secondary. Responsiveness to anesthetic blockade might better serve as a confirmational, rather than mandatory, criterion for diagnosis.
The present disclosure provides peptoid-based chelating ligands, corresponding cyclic peptoids, and methods of making thereof. Functional groups may be tailored for high metal binding affinity and selectivity. The side chains of a cyclic peptoid according to the present disclosure may be selected based on, for example, high affinity for actinide or other metal ions, selectivity for actinide or other metal ions, the ability to recover a metal once it is bound to the peptoid, and whether the overall peptoid should be hydrophobic or hydrophilic. Unlike siderophores, peptoid-based chelating ligands of the present disclosure are not readily hydrolyzed under physiological conditions. Therefore, peptoid-based chelating ligands may be, for example, used to treat actinide (e.g., iron and lead) poisoning in vivo. Moreover, peptoid-based chelating ligands of the present disclosure may be used for medical imaging, chelation therapy, drug delivery, and separation technologies, for example.
The invention discloses an oral medicine composition consisting of berberine and melbine, which is applied to field of compound medicinal preparations, as well as a preparation method thereof. The oral medicine composition consists of active medicine components and auxiliary medicinal preparation materials; the active medicine components consist of berberine or pharmaceutically acceptable salt thereof and melbine or pharmaceutically acceptable salt thereof. The pharmaceutically acceptable salt is selected from one of hydrochloride and sulfate. The medicine composition is common tablet, double-layer tablet, enteric coatel tablet, capsula, granula and powder. The medicine composition is a medicine composition for reducing blood sugar and blood fat, and preventing and treating diabetic complication. The product of the invention is simple in formula; the berberine and melbine have good dissolution rate; the medicine composition has good stability; the berberine hydrochloride and melbine hydrochloride have suitable weight in unit dosage of medicine composition; and the preparation method is simple, short in operation time and low in cost.
Innate immunity in asthma may be influenced by alterations in lung microbiota, potentially affecting disease severity. This study investigates the differences in lung inflammation and microbiome between asthma-ovalbumin (OVA) administered with and without fluconazole treatment in C57BL/6 mice. Additionally, the role of inflammation was examined in an in vitro study using a pulmonary cell line. At 30 days post-OVA administration, allergic asthma mice exhibited increased levels of IgE and IL-4 in serum and lung tissue, higher pathological scores, and elevated eosinophils in bronchoalveolar lavage fluid (BALF) compared to control mice. Asthma inflammation was characterized by elevated serum IL-6, increased lung cytokines (TNF-α, IL-6, IL-10), and higher fungal abundance confirmed by polymerase chain reaction (PCR). Fluconazole-treated asthma mice displayed higher levels of cytokines in serum and lung tissue (TNF-α and IL-6), increased pathological scores, and a higher number of mononuclear cells in BALF, with undetectable fungal levels compared to untreated mice. Lung microbiome analysis revealed similarities between control and asthma mice; however, fluconazole-treated asthma mice exhibited higher Bacteroidota levels, lower Firmicutes, and reduced bacterial abundance. Pro-inflammatory cytokine production was increased in supernatants of the pulmonary cell line (NCI-H292) after co-stimulation with LPS and beta-glucan (BG) compared to LPS alone. Fluconazole treatment in OVA-induced asthma mice exacerbated inflammation, partially due to fungi and Gram-negative bacteria, as demonstrated by LPS+BG-activated pulmonary cells. Therefore, fluconazole should be reserved for treating fungal asthma rather than asthma caused by other etiologies.
Arm 3f: NUC-3373, LV and oxaliplatin at dose levels used in Arm 2a may be administered in subsequent cetuximab cohorts. NUC-3373+LV may be administered weekly or every other week, oxaliplatin will be administered every other week and cetuximab will be administered weekly.
This particular study aim is devoted to the piloting of a brief motivational intervention to reduce alcohol misuse and consequences among sexual minority women. The objective of this study aim is to examine the preliminary feasibility and acceptability of the intervention following treatment development and refinement. Participants will be randomized to a brief intervention or an attention-matched control arm. Participants in both conditions will complete: a baseline survey as well as a follow-up assessment at 1- and 4-months post-intervention. The investigators hypothesize that the developed intervention will be feasible (as indicated by the number of women eligible who consent, attend their intervention session, and return for follow up). The investigators also hypothesize that the intervention will be acceptable to sexual minority women. The investigators will also obtain preliminary evidence of intervention efficacy in terms of alcohol use outcomes. Specifically, the investigators hypothesize that participants in the intervention will report less frequent heavy episodic drinking and fewer alcohol consequences post-intervention compared with those in the control group.
A few cases of anaphylactic/anaphylactoid reactions are reported in the postmarketing use of DOTTI. Involvement of skin (hives, pruritus, swollen lips-tongue-face) and either respiratory tract (respiratory compromise) or gastrointestinal tract (abdominal pain, vomiting) are noted.

Angioedema involving eye/eyelid, face, larynx, pharynx, tongue and extremity (hands, legs, ankles, and fingers) with or without urticaria requiring medical intervention are reported in the postmarketing use of DOTTI. Angioedema involving the tongue, glottis, or larynx, may result in airway obstruction. Do not give DOTTI to any woman who develops angioedema during treatment with DOTTI.

Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema. 

Consider whether the benefits of estrogen therapy outweigh the risks in such women.
The specific research question posed was 'Is a healthy lifestyle intervention using Social Cognitive Theory (SCT)-based PA and dietary strategies implemented for 12 weeks through face-to-face group sessions and social media tools effective in the initiation and maintenance of increased PA level and healthy balanced dietary intake, resulting in improvements of T2DM risk score, anthropometrics, metabolic parameters and SCT-related psychosocial factors among Bruneian young adults at risk of T2DM?'.

Study design was two-arm parallel, stratified with simple randomisation, and assessor-blinded randomised controlled trial. Participants were randomly allocated into intervention group and control group. Participants were students and alumni of Universiti Brunei Darussalam and Universiti Teknologi Brunei who were overweight-obese at risk of T2DM with a mean age of 23.1 (2.48) years old. Intervention group went through a healthy lifestyle intervention using evidence-based SCT strategies emphasising on PA and diet for 12 weeks, while the control group only received leaflets on healthy lifestyle with no further guidance. Outcomes measured were changes from baseline at week 0 to post-intervention at week 13 between intervention and control groups. Outcomes were changes in diabetes risk score, anthropometrics, metabolic parameters, PA, dietary intake and SCT-related psychosocial factors, with repeated-measures ANOVA as the main analysis.
More than half of older adults are frail or prefrail in the United States, and hospital-associated deconditioning likely increases this risk. However, the impact of frailty on potential functional improvements after hospital discharge is poorly understood. We sought to identify the influence of baseline frailty on gait speed change in older adults receiving home health physical therapy (PT) after hospital discharge. The severity of frailty was assessed using Cardiovascular Health Study frailty criteria (weakness, slowness, weight loss, physical inactivity, and exhaustion). Gait speed was measured at baseline and 60-days post-hospital discharge. Upon admission to home health rehabilitation services, half of older adults (total N=250) were considered frail, with slowness (90%) and weakness (75%) being the most common characteristics. Older adults, whether pre-frail or frail, demonstrated similar and clinically meaningful improvements in gait speed after receiving home health rehabilitation for 60 days following hospital discharge. These results suggest that clinicians caring for older adults in the hospital can counsel both pre-frail and frail patients that, with home health rehabilitation, clinically significant improvements in function can be expected over the 2 months following discharge. Furthermore, we observed encouraging gait speed improvement with physical therapy following hospitalization in older adults. Results can inform anticipatory guidance on hospital discharge.
The antiviral treatment, interferon-α with ribavirin, has been used in treating chronic hepatitis C patients to prevent the development of liver cirrhosis and hepatocellular carcinoma. However, the duration of this treatment needs at least 6 months and severe side effects such as anemia, fatigue, depression with suicidal thoughts can occur at any time throughout the treatment. There has been no study related to the issue of the risk to the population of developing these severe side effects and failing the treatment. Therefore, the aims of this three-year study are to explore symptom experience and its related factors for the patients with chronic hepatitis C Infection receiving interferon-α with ribavirin for 24 weeks and further to develop a prediction model for individuals to predict the relative risk of failure or occurence of severe side effects which interrupt the treatment. Patients will be recruited from outpatients in two hospitals in Northern and Middle Taiwan. A longitudinal study is designed with a one-year follow-up at pre-treatment, and at the 1, 2, 4, 6, 8, 12,16,20, 24 weeks during treatment, and at the 4, 12, 24 weeks of post-treatment. The basic information including the laboratory data, the Symptom Distress Scale, the Fatigue Symptom Inventory, the Hospital Anxiety and Depression Scale, MOS, and the Short-Form 12 Health-Related Quality of Life questionnaires will be used to assess patients' demographic characteristics, symptom experience, fatigue, depression, anxiety, sleep disturbance, and quality of life during the treatment. Three hundred patients will be interviewed within three years. The data will be analyzed using descriptive, independent t-test, Pearson's correlation, Analysis of Variances, generalized estimating equations, logistic regression, and classification tree. We expect this study to explore the characteristics of the population with high risks of treatment failure to severe side effects during treatment in Taiwan. In addition, the results can provide the information for clinicians and researchers to tailor interventions to individual needs.
A composition for promoting hair growth and restoration comprising a non-polar organic solvent fraction of Chrysanthemum zawadskii var. latilobum is provided to promote the hair growth by shortening a period between interphase and a growth period of air without side effects. A composition for promoting hair growth and restoration comprises an organic solvent fraction of Chrysanthemum zawadskii var. latilobum as an effective ingredient, wherein the organic solvent fraction is a second extract fraction prepared by extracting the Chrysanthemum zawadskii var. latilobum with a first extraction solvent and then extracting the first extract with a second extraction, wherein the first extraction solvent is at least one solvent selected from the group consisting of purified water, a lower alcohol such as methanol, ethanol, isopropyl alcohol, and n-butanol, a polyhydric alcohol such as glycerol, ethylene glycol, propylene glycol, and 1,3-butylene glycol, and a hydrocarbon-based solvent such as methyl acetate, ethyl acetate, benzene, n-hexane, diethylether, dichloromethane and chloroform and the second extraction solvent is at least one selected from the group consisting of petroleum ether, methylacetate, benzene, hexane, chloroform. ethylene chloride, dimethyl ether, and ethyl acetate. A method for preparing the composition comprises the steps of: (a) washing and finely cutting stems and leaves of the Chrysanthemum zawadskii var. latilobum; (b) precipitating the cut Chrysanthemum zawadskii var. latilobum in the first extraction solvent for 1-10 days at a temperature of 18-27 deg.C; (c) filtering, concentrating and freeze-drying the first extract to obtain a dried extract of the Chrysanthemum zawadskii var. latilobum; (d) dissolving the dried extract in water; and (e) extracting the aqueous solution of the Chrysanthemum zawadskii var. latilobum with at the second extraction solvent. A hair cosmetic composition such as shampoo, rinse, ample and treatment comprises the composition for promoting hair growth and restoration. Further, the composition for promoting hair growth and restoration is one selected from liquid agent for external use, cream, ointment, paste, aerosol agent, gel and wax.
PCT No. PCT/DE93/00572 Sec. 371 Date Dec. 22, 1994 Sec. 102(e) Date Dec. 22, 1994 PCT Filed Jun. 24, 1993 PCT Pub. No. WO94/00109 PCT Pub. Date Jan. 6, 1994The invention relates to a dermatological agent for assisting the transport of oxygen in the skin, a process for its preparation and the use thereof. The problem with the known dermatological agents is the inadequate supply of oxygen to the skin and the adjoining tissue. The object of the invention is therefore to get through the horny layer of the skin and the epidermis by penetration processes in order to increase the oxygen concentration in the dermal area and adjoining tissue and to activate metabolic processes. According to the invention, this is effected by means of a dermatological agent containing asymmetric lamellar aggregates, consisting of phospholipids and oxygen-laden fluorocarbon or fluorocarbon mixture, the amount of fluorocarbon being in the range from 0.2 to 100% weight/volume, in a carrier which is suitable for dermatological use. Preparation is effected by emulsification of the corresponding constituents, and use in ointments, creams, lotions, waters, alcoholic extracts, pastes, powders, gels, tinctures or on dressings and plasters or in a spray.
IN BRIEF: Repro57 mice, bearing an Rnf212 gene mutation, exhibit infertility in both homozygous mutant males and females, revealing arrested spermatogenesis in males and investigating unclear mechanisms in females. The study highlights aneuploidy and altered kinetochore patterns in repro57 homozygous mutant oocytes, which impact later stages of embryo development.
ABSTRACT: Repro57 mice, induced with N-ethyl-N-nitrosourea and harboring a mutation in the Rnf212 gene, exhibit infertility in both homozygous mutant males and females. Rnf212 plays a crucial role in recombination and crossover designation. In male repro57 homozygous mutants, spermatocytes often degenerate during late prophase, and mature spermatozoa are absent in the seminiferous epithelium, indicating arrested spermatogenesis as the cause of infertility. Despite reports of infertility in Rnf212-knockout female mice, the specific mechanisms underlying infertility in female repro57 homozygous mutants remain elusive. This study investigates the chromosomal and kinetochore patterns of mature oocytes and their developmental potential following in vitro fertilization in female repro57 homozygous mutant mice. While all wild-type oocytes progress to metaphase II and exhibit euploidy, all repro57 homozygous mutant mouse oocytes display aneuploidy. Additionally, kinetochore distances in repro57 homozygous mutant oocytes exceed those observed in wild-type counterparts. Although no significant differences are noted in fertilization and early embryo development rates between wild-type and repro57 homozygous mutant mice, embryos derived from repro57 homozygous mutants exhibit significantly lower morula and blastocyst rates, accompanied by frequent cytokinesis failure and vacuole formation. These findings suggest that the premature segregation of sister chromatids in repro57 homozygous mutant mice adversely impacts the later stages of embryo development.